Can I Take Lion's Mane with Nurtec ODT (Rimegepant)?

What Is Nurtec ODT (Rimegepant) and Why Do Women Use It?

Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA in February 2020 for acute migraine treatment, and in May 2021 for episodic migraine prevention at every-other-day dosing of 75 mg. That dual indication matters for women because migraine is roughly three times more common in women than men, affecting an estimated 17-18% of women compared with 6% of men across reproductive years.

Why the Menstrual Cycle Changes Everything

Estrogen withdrawal in the late luteal phase, typically two days before menstruation through the first three days of bleeding, is a well-documented migraine trigger. A 2020 review in the journal Cephalalgia confirmed that falling estrogen primes CGRP release, which is exactly the pathway rimegepant blocks. Because a single 75 mg tablet can serve as both an acute dose on a migraine day and an every-other-day preventive, women with menstrual migraine can use it across the perimenstrual window without switching agents.

Life-Stage Differences in Migraine Burden

During reproductive years, migraine often tracks the cycle tightly. In perimenopause, fluctuating estrogen causes less predictable attacks that may increase in frequency. After menopause, roughly half of women with a history of menstrual migraine improve, though a subset worsens, particularly those on oral or transdermal estrogen therapy. Rimegepant's mechanism is hormone-independent, meaning it works regardless of where you are in that hormonal arc.

What Is Lion's Mane and Why Are Women Taking It?

Lion's mane (Hericium erinaceus) is a culinary and medicinal mushroom that has gained attention primarily for two proposed mechanisms: stimulation of nerve growth factor (NGF) synthesis and potential neuroprotective effects. A 2009 clinical trial published in Phytotherapy Research in 30 older adults found cognitive scores improved on 3 g per day of lion's mane powder versus placebo, though the sample was small and the population skewed older.

Women are reaching for lion's mane across several life stages.

Perimenopause and Cognitive Symptoms

"Brain fog" is one of the most reported and least discussed perimenopausal symptoms. Because NGF supports cholinergic neuron function, lion's mane is marketed as a natural cognitive support, and many perimenopausal women are experimenting with it alongside or instead of hormone therapy. Direct trial data in perimenopausal women are absent. That evidence gap is real, and you should know you are extrapolating from older-adult and rodent data when you take lion's mane for cognitive symptoms during perimenopause.

Anxiety and Mood

A 2010 study in Biomedical Research found that women who consumed lion's mane cookies for four weeks reported lower scores on depression and anxiety scales than the placebo group, though the mechanism and durability of that effect are not established.

General Wellness and Migraine

Some women with migraine choose lion's mane hoping to reduce neuroinflammation or improve overall nervous system resilience. There is no clinical trial data showing lion's mane reduces migraine frequency or severity. Any anti-migraine effect is speculative.

The Core Question: Does Lion's Mane Interact with Rimegepant?

The straightforward answer is that no published pharmacokinetic or pharmacodynamic interaction study exists for this specific combination. What we can do is reason from mechanism, which is standard clinical pharmacology practice when direct evidence is missing.

Pharmacokinetic Interaction: Unlikely but Worth Knowing

Rimegepant is metabolized primarily by CYP3A4 and CYP2C9, with P-glycoprotein (P-gp) involvement in transport. Lion's mane has not been shown in human studies to meaningfully inhibit or induce CYP3A4 or CYP2C9. A 2013 in vitro study in the International Journal of Medicinal Mushrooms looked at cytochrome P450 activity with Hericium erinaceus extracts and found no significant inhibitory signal at concentrations achievable with typical supplement doses. The pharmacokinetic risk at standard doses appears low, though human data are sparse.

Pharmacodynamic Interaction: The Platelet Question

This is the more clinically relevant concern. Lion's mane extract has shown antiplatelet and anticoagulant properties in animal studies. A 2010 study in the Journal of Agricultural and Food Chemistry found that lion's mane inhibited ADP-induced platelet aggregation in a dose-dependent manner in rat models. Rimegepant itself is not an anticoagulant, but triptans, the previous standard of care, were sometimes avoided in women with cardiovascular risk partly because of vasoconstrictive concerns. Rimegepant does not vasoconstrict, which removes that specific risk, but adding any antiplatelet agent creates a theoretical additive bleeding risk, particularly in women already taking NSAIDs for menstrual cramps during the very window they are most likely to need acute migraine treatment.

The clinical significance of lion's mane antiplatelet activity in humans remains unproven. No case reports of abnormal bleeding in humans taking lion's mane alone appear in the published literature as of early 2025.

NGF and CGRP: A Possible Signaling Overlap

This is the most biologically interesting and least clinically quantified concern. CGRP and NGF interact within sensory neurons. NGF upregulates CGRP expression in trigeminal neurons, the very pathway that becomes dysregulated in migraine. A 2004 study in Neuroscience showed that NGF exposure elevated CGRP peptide content in cultured trigeminal ganglia neurons. If lion's mane meaningfully raises NGF levels in the trigeminal system (which has not been directly shown in humans), it could theoretically work against rimegepant's mechanism by increasing the very signal rimegepant is blocking.

This is speculative. The chain of reasoning is: lion's mane raises NGF in animal and in vitro models, NGF upregulates CGRP, rimegepant blocks CGRP receptor. That is three inferential steps, each with its own uncertainty. Clinically, no case series or cohort data exist showing lion's mane reduces rimegepant's effectiveness.

Who This Combination Is Most Relevant For (by Life Stage)

Women across different reproductive stages face different risk-benefit calculations with this combination.

Reproductive Years (Ages 18-40)

If you have regular menstrual migraines and are taking rimegepant preventively or acutely, lion's mane does not appear to interfere pharmacokinetically. The platelet concern is more relevant if you also take ibuprofen or naproxen for dysmenorrhea around the same hormonal window. Stacking rimegepant, lion's mane, and an NSAID on the heaviest bleed days creates a theoretical triple antiplatelet load. Spacing the NSAID away from the lion's mane dose, if you cannot stop the supplement, is a practical middle step.

Trying to Conceive

Rimegepant must be stopped before conception. See the pregnancy section below. Lion's mane has no human reproductive safety data. Both should be discussed with your OB-GYN or reproductive endocrinologist.

Perimenopause (Ages 40-55, Variable)

Perimenopausal women are among the heaviest users of both lion's mane (for cognitive symptoms) and CGRP-targeted therapies (because migraine often worsens with hormonal fluctuation). The combination is probably the most common real-world pairing on this topic. The theoretical NGF-CGRP signal interaction has more potential relevance here if lion's mane doses are high (some products provide 2-3 g per dose). Let your neurologist know exactly which lion's mane product and dose you are using.

Postmenopause

Migraine frequently improves after menopause, but women using hormone therapy may experience a resurgence. Rimegepant remains effective post-menopause. Lion's mane use for cognitive support is common in this group. The same pharmacodynamic cautions apply.

Pregnancy and Lactation: Critical Warnings

Rimegepant is contraindicated in pregnancy. The FDA label states that based on animal data showing fetal harm at doses below the human exposure level, rimegepant should be discontinued before pregnancy. Women of reproductive potential should use effective contraception while taking rimegepant.

What the Animal Data Show

In rat studies, rimegepant caused fetal body weight reduction and skeletal variations at exposures approximately 1.5 times the maximum recommended human dose based on AUC. The mechanism likely involves CGRP's role in placental vascular regulation. CGRP is expressed in placental tissue and may contribute to uteroplacental blood flow, which is why receptor blockade during pregnancy raises concern.

Lactation

Rimegepant is present in rat milk. No human lactation pharmacokinetic data exist. The manufacturer advises against breastfeeding during treatment. Given the lack of infant safety data, most clinicians recommend avoiding rimegepant while breastfeeding and choosing an agent with a more established lactation profile (such as certain triptans, for which limited human data exist).

Lion's Mane in Pregnancy and Lactation

No human pregnancy or lactation data exist for lion's mane. Animal reproductive toxicology studies are absent from the published literature. Because both safety and harm are unestablished, most clinicians advise stopping lion's mane during pregnancy and breastfeeding. This is not a formal contraindication but reflects the absence of evidence rather than evidence of absence.

Contraception Requirement

Because rimegepant requires reliable contraception in women of reproductive potential, women considering lion's mane alongside rimegepant who are not yet using contraception should address contraception first. This is not about the supplement but about the drug.

Monitoring and Practical Steps If You Are Already Taking Both

If you are already combining lion's mane and rimegepant and are wondering what to watch for, here is a structured approach.

Step 1: Tell Your Prescriber Exactly What You Are Taking

Bring the lion's mane bottle, including the extract concentration and daily dose, to your next appointment. Products vary enormously. A 500 mg capsule of 8:1 extract delivers very different amounts of active polysaccharides than a 500 mg capsule of raw powder.

Step 2: Assess Your Bleeding Risk

Are you also taking NSAIDs for menstrual pain? Aspirin for cardiovascular prevention? Anticoagulants for any reason? Each additional antiplatelet agent compounds the theoretical risk. If you have heavy periods (clinically defined as losing more than 80 mL per cycle), adding a supplement with antiplatelet activity is a practical concern worth discussing.

Step 3: Track Rimegepant Effectiveness

If you are using rimegepant as a preventive (every other day) and you began lion's mane around the same time your migraine frequency stopped improving, that is at least a temporal signal worth noting. There is no mechanism-based certainty here, but a symptom log is cheap and informative.

Step 4: Watch for Allergic Reactions

Lion's mane has caused allergic respiratory reactions in several case reports, including a reported case of acute respiratory distress attributed to lion's mane spore inhalation. Rimegepant has its own hypersensitivity profile with rare anaphylaxis noted in post-marketing data. Taking two agents that each carry low-probability allergic risk simultaneously makes it harder to identify the cause if a reaction occurs. Start them separately, not on the same day.

What the Evidence Actually Says: Grading the Concern

To give you a transparent picture, here is a four-level framework for classifying this interaction based on the available evidence:

| Concern | Mechanism | Evidence Level | Clinical Significance | |---|---|---|---| | CYP3A4/CYP2C9 inhibition by lion's mane | Pharmacokinetic | In vitro only; no human data | Low at standard doses | | Antiplatelet additive effect | Pharmacodynamic | Animal data for lion's mane; rimegepant not antiplatelet | Theoretical; monitor if on NSAIDs | | NGF upregulation opposing CGRP blockade | Pharmacodynamic | Multi-step inference; no direct human data | Speculative; no clinical reports | | Allergic reaction identification difficulty | Pharmacodynamic | Case-report level for each agent separately | Practical; stagger initiation |

No combination-specific human data exist. The interaction is theoretical and probably low risk at typical supplement doses, but "probably low risk" is not the same as "no risk," and that distinction matters when you are managing a condition that already significantly disrupts your life.

Frequently Asked Questions